Chief Scientific Officer and Co-Founder Jonathan Rittichier to Speak on Oligonucleotide Chemistry, Manufacturing and Controls Panel

EnPlusOne Biosciences, Inc., a biotechnology company harnessing the power of enzymes to deliver sustainable RNA at scale, today announced that co-founder and Chief Scientific Officer Jonathan Rittichier, PhD, will be presenting recent advances in the company’s ezRNA™ platform at TIDES USA 2024 in Boston on Thursday, May 16, 2024 at 9 am. The three-day event, at the Hynes Convention Center, brings together scientists and companies focused on the use of oligonucleotides and peptides in therapeutics.

Dr. Rittichier’s presentation will highlight recent technical developments and upcoming milestones that differentiate the company’s proprietary enzymatic RNA oligonucleotide synthesis technology. He will describe how its revolutionary innovations are designed to enable the delivery of synthetic, modified RNA at commercial scale to life science companies, addressing a significant need in the industry. His presentation is part of a panel on Oligonucleotide Chemistry, Manufacturing and Controls at the event.

Dr. Rittichier said, “We are very excited about EnPlusOne’s advances in building out our ezRNA™ synthesis platform and we look forward to discussing them with leaders in R&D from around the world.”

Co-founder and COO Dan Ahlstedt added, “Our platform will demonstrate EnPlusOne’s leadership in enzymatic oligonucleotide synthesis, moving RNA synthesis beyond the recognized challenges and limitations associated with current chemical synthesis approaches.”

In addition to Dr. Rittichier’s presentation, another co-founder, George Church, PhD, Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard and MIT and leader of the Wyss Institute’s Synthetic Biology platform, will deliver a keynote presentation on Machine Learning + Multiplex Libraries on Wednesday, May 15 at 9 am.

EnPlusOne Biosciences is a technology spinout from the Wyss Institute for Biologically Inspired Engineering at Harvard University and is backed by lead investor Northpond Ventures alongside Breakout Ventures, Coatue, and individual investors.

About EnPlusOne Biosciences

EnPlusOne is enabling the future of RNA therapeutics. Its ezRNA™ platform is a revolutionary innovation that harnesses the power of enzymes to synthesize RNA and can incorporate a diverse array of natural and modified nucleotides. Their enzymatic, water-based approach promises to unlock sustainable and scalable commercial manufacturing of RNA therapeutics. For more information, please visit www.enplusonebio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240514795900/en/